Literature DB >> 12826895

Peripheral medulloepithelioma: an immunohistochemical, ultrastructural, and cytogenetic study of a rare, chemotherapy-sensitive, pediatric tumor.

Ludvik R Donner1, Ikuko Teshima.   

Abstract

A case of peripheral medulloepithelioma, a rapidly growing tumor involving the pelvic cavity of a 12-year-old girl, is presented. The diagnosis was supported by expression of vimentin, nestin, alpha-internexin, neurofilaments, and microtubule-associated protein 5 and by characteristic ultrastructure that included absence of cilia or microvilli. Trisomy of chromosomes 2 and 8 was the only detectable chromosomal abnormality. Combination chemotherapy resulted in complete remission. Because some of these rare tumors are sensitive to chemotherapy, their recognition and separation from other neuroectodermal tumors are advisable for better understanding of their biology and determination of optimal treatment.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12826895     DOI: 10.1097/00000478-200307000-00018

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  3 in total

Review 1.  Extracranial medulloepithelioma: a review of the literature.

Authors:  David Bailey; Christine Mau; Christina Toepke; Elizabeth Finch; Elias Rizk
Journal:  Childs Nerv Syst       Date:  2022-04-27       Impact factor: 1.532

2.  Nestin expression in osteosarcomas and derivation of nestin/CD133 positive osteosarcoma cell lines.

Authors:  Renata Veselska; Marketa Hermanova; Tomas Loja; Petr Chlapek; Iva Zambo; Karel Vesely; Karel Zitterbart; Jaroslav Sterba
Journal:  BMC Cancer       Date:  2008-10-16       Impact factor: 4.430

3.  Peripheral medulloepithelioma: a rare tumor with a potential target therapy.

Authors:  Maria Debora De Pasquale; Maria Antonietta De Ioris; Angela Gallo; Angela Mastronuzzi; Alessandro Crocoli; Raffaele Cozza; Renata Boldrini
Journal:  J Transl Med       Date:  2014-02-21       Impact factor: 5.531

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.